由于一名试验病人肝脏可能受损,辉瑞停止了减肥药丸的研制。 Pfizer halts weight loss pill development due to potential liver damage in a trial patient.

Pfizer在试验中一位病人肝酶升高,表明肝脏可能受损后,停止研制每天新的减肥药丸Danuglipron。 Pfizer has halted the development of its new daily weight loss pill, danuglipron, after a patient in a trial experienced elevated liver enzymes, indicating potential liver damage. 尽管遭受挫折,辉瑞仍然致力于研制其他减肥药物。 Despite the setback, Pfizer remains committed to developing other weight loss drugs. GLP-1市场包括有助于抑制食欲和调控血糖的药物,预计到2030年代初将价值超过1 500亿美元。 The GLP-1 market, which includes drugs that help suppress appetite and regulate blood sugar, is expected to be worth over $150 billion by the early 2030s.